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The blood pressure was measured on sitting position and the mean of three readings recorded. Pulse and mean arterial pressures calculated using the following formula: Pulse pressure (mm Hg) = Systolic blood pressure -diastolic blood pressure Mean arterial blood pressure = Diastolic blood pressure + 1/3 (Pulse pressure)Participants enrolled in the study subjected to echocardiography (B mode) investigation. The echocardiography investigation performed from the patient left side so that the transducer (with a frequency of 2-4MHz) is at the long axis of the heart. Echocardiography data that related to systolic and diastolic left ventricular dysfunction were recorded and these included: shortening fraction (%), stroke vol-
INTRODUCTION
Interleukin-2 (IL-2) is a growth factor played a role in activation, and maturation of T lymphocytes. Functional IL-2 receptors (IL-2R) were expressed on activated B cells, dendritic cells, natural killer cells, and eosinophils. The functional importance of IL-2R was identified in tumorigenesis (1) . Soluble IL-2R-alpha (sIL-2Rα) released directly from the surface of neoplastic cells thus reflecting the tumor bulk, turnover and activity (2) . High concentrations of soluble (sIL-2R) detected in sera from healthy subjects and are increased in subjects with autoimmune disease including type 1 diabetes (3), inflammation and infection (4). In type 2 diabetes (T2D) complicated with atherosclerosis, high circulating sIL-2R is detected even in the absence of obesity and marked hyperglycemia (5) . In experimental animal model of myocardial infarction, it was observed that single injection of recombinant human interleukin-2 improved angiogenesis and preserved heart function via activation the natural killer cells and thereby contributed in vascular remodeling (6) . In heart failure of whatever cause, serum sIL-2R level is high before treatment, and then reduced after using therapeutic agents with pleiotropic effects like statins (7) . Recent study shows that sIL-2R level is high in patients with acute coronary syndrome in presence of systolic dysfunction or acute heart failure, and the levels of sIL-2R were proportional to left ventricle end-diastolic diameter and endsystolic diameter (8) . Cardiometabolic risk factors as well as abnormal ventricular function often exited in diabetic patients. Therefore, the rational of this study is to prove that inflammatory process plays a role in cardiac complications in diabetic patients presented with metabolic syndrome features. This study aimed to demonstrate that sIL-2R level (as a marker of inflammatory process) could be used to explain the association between the cardiometabolic risk factors (using the criteria of metabolic syndrome) and changes in ventricular function assessed by echocardiography in T2D.
MATERIALS AND METHODS
This study conducted in Departments of Pharmacology and Physiology, College of Medicine, Al-Mustansiriya University in cooperation with Laboratories of Al-Yarmouk Teaching hospital in Baghdad, Iraq. The study approved by an institutional review committee and informed consent obtained from each patient prior to admit in the study. This study was designed as a cross sectional in co- Peripheral venous blood samples were obtained, then the samples were centrifuged at 2500 rpm for 10 min., and the sera were separated for determination of fasting serum glucose, lipid profile (total cholesterol, triglycerides, high density lipoprotein-cholesterol and calculated atherogenic index which is equal to the ratio Triglycerides/ (High density lipoprotein) ) and sIL-2R using the technique of enzyme linked immunnosorbent assay (ELISA).
The patients categorized according to the presence of metabolic syndrome components. According to the National Cholesterol Education program (NCEP) definition, metabolic syndrome is present if a subject has three or more of the following (9) 
RESULTS
Fifty-two patients (12 male and 40 female) with a mean age of 57 years enrolled in this study. Table 1 showed that approximately 60% of patients were obese and most of them presented with central obesity by the evidence of waist circumference and waist/hip ratio. Table 2 showed that the mean systolic and diastolic blood pressures were at the hypertensive levels ( Table 2 ). The fasting lipid profile of patients showed high mean serum level of triglycerides and atherogenic index (Table 3) . No significant differences in echocardiography data that related to systolic dysfunction or to the gathered components of metabolic syndrome observed. The mean value of ejection fraction was 56.3%, which is below the cut-off value of healthy subjects. Figure 1 shows that twelve out of fifty two patients (23.1%) have ejection fraction below 50% and these values do not relate to the clustering components of metabolic syndrome. The mean value of serum sIL-2R was 3.469±3.062 pg/ml (range: 1.316-12.5). Ten out of fiftytwo patients have serum level of sIL-2R > 4 pg/ml and these values do not relate to the clustering components of metabolic syndrome (Figure 2 ). Serum IL-2R inversely and non-significantly correlated with ejection fraction (r = -0.12) and atherogenic index (r = -0.148) (Figures 3  and 4 ).
DISCUSSION
The results of this study demonstrate that T2D patients presented with metabolic syndrome have left ventricular dysfunction that does not relate to components of metabolic syndrome. The left ventricular dysfunction assessed by ejection fraction does non-significantly correlate with serum sIL-2R level. Most studies investigated the serum level of sIL-2R in type 1 diabetes with or without complications. The results of this study are in agreement with that reported by Pereira et al who demonstrated that the significant high level of sIL-2R in T2D did not relate to the components of metabolic syndrome including obesity and hyperglycemia (5) . Therefore, the obtained results indicated the presence of organ dysfunction resulted from systemic inflammatory response in T2D patients by the evidence that high serum sIL-2R is previously reported as a predictor marker of organ dysfunction (10) . Further study reported that the elevated plasma sIL2r is associated with progressed calcification of coronary artery which independent to the traditional coronary artery disease risk factors in type 1 diabetic and non-diabetic young adults (11) . Type 2 diabetic patients with metabolic syndrome have a greater incidence and absolute progression of coronary artery calcification (12) . On the other hand, one meta analysis study reviewed twelve studies and the authors concluded that sIL-2R is not a useful inflammatory marker of coronary artery calcification (13) . In (14) . This study demonstrates such findings but in asymptomatic patients and in absence of acute myocardial infarction. The clinical significance of determination the serum sIL2R is still under investigation and conflicting data were reported in this concern. Cesari et al (15) found that serum sIL-2R is not an important cytokine in clinical as well as subclinical cardiovascular diseases whereas Limas et al (16) demonstrates significant higher sIL-2R levels in dilated cardiomyopathy compared with the ischemic heart disease in which significantly correlated with the left ventricular end-diastolic diameter but not with the LV ejection fraction.
The clinical implications of the results of this study are to utilize serum sIL-2R level as a marker in assessment left ventricular function in diabetes and to consider it in the criteria of metabolic syndrome. Immune therapy that targeted sIL-2R could be useful in management of ventricular dysfunction in diabetic patients. Limitations of the study included small sample size, variations in duration of diabetes and glycemic control. Therefore, it concludes that there is a link between the left ventricular systolic function and the circulating sIL-2R in asymptomatic T2D which does not relate to the associated components of metabolic syndrome.
